MS and Demyelinating Disorders

Helius reported promising results for its Portable Neuromodulation Stimulator, enhancing gait and balance in poststroke patients, with FDA submission planned.

Navigating insurance hurdles for multiple sclerosis treatments poses significant risks, as seen in a patient's devastating relapse after denied care.

Here's some of what is coming soon to NeurologyLive® this week.

The associate professor of neurology at Johns Hopkins detailed how artificial intelligence is shaping the future of neurology through its integration in clinical care, research, and medical education. [WATCH TIME: 4 minutes]

A recent research letter emphasized that meningitis could be a possible early manifestation of MOG antibody–associated disease, according to results previously published in an international study.

A recent survey revealed significant variability in treatment decisions for pediatric MOGAD, highlighting gaps in knowledge and the potential need for improved clinical guidelines.

Nuri Jacoby, MD, a neurologist at Maimonides Medical Center and SUNY Downstate, previewed his talk at the 2025 AUPN Annual Meeting on using simulation to evaluate nonclinical competencies like communication and professionalism. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A recent study reveals a decline in multiple sclerosis progression rates, highlighting the impact of improved treatments and the need for ongoing innovation in care.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 4, 2025.

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could reshape patient care.

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed the implementation of digital platforms and lifestyle-focused clinics to streamline MS care. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 20, 2025.

Helius Medical Technologies expands access to its PoNS device for patients with MS as Aetna joins major payers in coverage, enhancing treatment options.

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. [WATCH TIME: 5 minutes]

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.

The ExTINGUISH trial investigates inebilizumab's efficacy for NMDAR encephalitis, aiming to enhance treatment options for diverse patient populations.

The assistant professor of neurology at the Medical College of Wisconsin talked about the complexities of advanced multiple sclerosis, highlighting gaps in clinical trials and the need for individualized care strategies. [WATCH TIME: 3 minutes]

Recent MR analysis uncovers protein associations with neuromyelitis optica spectrum disorder, suggesting new treatment pathways and drug targets for improved management.

Here's some of what is coming soon to NeurologyLive® this week.